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Whole‑genome sequencing 
reveals KRTAP1‑1 as a novel 
genetic variant associated 
with antidepressant treatment 
outcomes
Jong‑Ho Park1,2,11, Shinn‑Won Lim1,11, Woojae Myung3,11, Inho Park4, Hyeok‑Jae Jang1, 
Seonwoo Kim5, Min‑Soo Lee6, Hun Soo Chang7, DongHo Yum8, Yeon‑Lim Suh8, 
Jong‑Won Kim1,9* & Doh Kwan Kim10*
Achieving remission following initial antidepressant therapy in patients with major depressive 
disorder (MDD) is an important clinical result. Making predictions based on genetic markers holds 
promise for improving the remission rate. However, genetic variants found in previous genetic studies 
do not provide robust evidence to aid pharmacogenetic decision‑making in clinical settings. Thus, 
the objective of this study was to perform whole‑genome sequencing (WGS) using genomic DNA to 
identify genetic variants associated with the treatment outcomes of selective serotonin reuptake 
inhibitors (SSRIs). We performed WGS on 100 patients with MDD who were treated with escitalopram 
(discovery set: 36 remitted and 64 non‑remitted). The findings were applied to an additional 553 
patients with MDD who were treated with SSRIs (replication set: 185 remitted and 368 non‑remitted). 
A novel loss‑of‑function variant (rs3213755) in keratin‑associated protein 1–1 (KRTAP1‑1) was 
identified in this study. This rs3213755 variant was significantly associated with remission following 
antidepressant treatment (p = 0.0184, OR 3.09, 95% confidence interval [CI] 1.22–7.80 in the discovery 
set; p = 0.00269, OR 1.75, 95% CI 1.22–2.53 in the replication set). Moreover, the expression level 
of KRTAP1‑1 in surgically resected human temporal lobe samples was significantly associated with 
the rs3213755 genotype. WGS studies on a larger sample size in various ethnic groups are needed 
to investigate genetic markers useful in the pharmacogenetic prediction of remission following 
antidepressant treatment.
Major depressive disorder (MDD) is one of the most common debilitating diseases that has major public health 
and economic  consequences1. Antidepressant medication provides effective treatment for patients with  MDD2,3. 
However, initial antidepressant treatment can fail in 30–40% of  patients4. Remission following depression treat-
ment has clinical importance because it is associated with functional recovery and a better  prognosis5. Moreo-
ver, antidepressant therapy takes time to achieve an effect, usually 2–4 weeks. Currently, it is not possible to 
predict which drug will be the most effective for an individual patient. There is a great deal of motivation on 
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the professional side to provide better treatments: genetic prediction represents a good starting point for such 
 improvements5.
The effects of antidepressants were demonstrated to have genetic  variability6–8. A single nucleotide polymor-
phism (SNP)-based heritability could explain up to 42% of the variance in antidepressant  responses9. However, 
genetic variants found in previous genome-wide association studies (GWASs) on the antidepressant response 
do not provide robust evidence to aid pharmacogenetic decision-making in clinical  settings10–16. Most whole-
sample analyses of genetic variants did not attain statistical significance at the genome-wide level. Additionally, 
there is no genetic variants robustly replicated, and none of these previous antidepressant pharmacogenetics 
studies identified significant SNPs related to  remission10–14. GWASs typically focused on common variants that 
represent only a small fraction of all variants related to the antidepressant mechanism of action. Consequently, 
the “common disease–common variant” hypothesis based on GWASs has not fulfilled expectations in the field of 
pharmacogenetics associated with  depression17.With the recent advances in genetic technology, whole-genome 
sequencing (WGS) has offers multiple advantages in genomic variant  discovery18. WGS can provide information 
regarding all genetic variants—rare variants, loss of function (LOF), functional intronic variants, and struc-
tural variants. Significant outcomes from studies on these variants can provide useful information to pinpoint 
causal genes and their associated pathways. LOF variants have been reported to significantly affect protein func-
tion and, as a result,  depression19,20 and pharmacogenomic traits of  antidepressants21. There have been several 
pharmacogenetic studies on antidepressant treatment response using genetic sequencing, including an exome 
 sequencing8,22,23, and a targeted sequencing  study24. Despite the advantages of WGS, studies with sufficient sample 
sizes have not yet been reported due to high cost and high computational  resources25.
Therefore, here, we conducted a preliminary WGS study to identify genetic variants associated with remission 
following antidepressant treatment in a discovery set with a small sample size (n = 100) along with a replication 
set (n = 553). Although it is difficult to obtain robust results using a small sample size, in this study, we tried to 
determine the applicability of WGS in this field. Our hypothesis was that genetic germline variants found using 
WGS might be associated with remission following antidepressant treatment with selective serotonin reuptake 
inhibitors (SSRIs).
Results
Subject characteristics. The subjects’ clinical and demographic characteristics of the subjects are shown 
in Table 1. The subjects were mostly elderly individuals (median age 68 and 62 years for the discovery and rep-
lication sets, respectively) who were experiencing their second or later MDD episodes. Approximately one-fifth 
of these patients had a family history of depression. The pretreatment Hamilton scale for depression (HAM-D) 
scores indicated moderate to severe depression (median score 19 and 20 for the discovery and replication sets, 
respectively). The observed remission rates were above 30% for both the discovery and replication sets. Age and 
age at onset differed between the discovery and replication sets. Family history of depression, number of epi-
sodes, and baseline HAM-D score in the discovery set and sex and baseline HAM-D score in the replication set 
were associated with remission following antidepressant treatment.
WGS characteristics. We conducted WGS for 100 patients with MDD treated with SSRIs. The average 
depth showed a 31.8 × coverage of the whole genome. All patients with MDD in the discovery set were confirmed 
to be ethnically homogeneous; thus, there was no population stratification (Supplementary Fig. S1). The average 
transition/transversion (Ts/Tv) ratio, computed as a quality control (QC) parameter in the whole genome using 
the SNV data, was 1.97. This value is generally around 2.0 based on previous WGS  reports26. By applying a QC 
filter (as mentioned in the “Methods”), the final call set contained 13,318,214 variants comprising 9,736,393 
single nucleotide variations (SNVs) and 3,581,821 insertions and deletions (INDELs). Of these 13,318,214 vari-
ants, 8,871,350 SNVs and 1,896,224 INDELs matched with variants from the dbSNP 138 database. The number 
of novel variants that did not match with dbSNP was 865,043 for SNVs (8.88%) and 1,685,597 for INDELs 
Table 1.  Clinical and demographic characteristics of the completer cohorts. HAM-D Hamilton depression 
rating score, SSRIs selective serotonin reuptake inhibitors. a Chi-square test was performed. b Wilcoxon’s rank 
sum test was performed. Ranges shown are inter-quartile ranges.
Characteristics
Discovery set (n = 100) Replication set (n = 553)
p (Discovery set 
vs. replication set)
Escitalopram-treated group SSRI-treated group
Total With remission Without remission p Total With remission Without remission p
Remission rate 36 (36.0%) 185 (33.5%) 0.62
Response rate 60 (60.0%) 299 (54.1%) 0.27
Sex, female (%)a 74 (74.0%) 25 (69.4%) 49 (76.6%) 0.44 418 (75.6%) 152 (82.2%) 266 (72.3%) 0.01 0.74
Age,  yearb 68 (59–72) 67 (61.5–73.5) 69 (58–72) 0.80 62 (51–69) 61 (48–68) 62 (52–70) 0.15  < 0.0001
Family history of 
depression (%)a 16 (16.0%) 2 (5.6%) 14 (21.9%) 0.03 108 (19.5%) 33 (17.8%) 75 (20.4%) 0.48 0.41
Number of  episodesb 2 (1–2.5) 1 (1–2) 2 (1–3) 0.01 2 (1–2) 2 (1–2) 2 (1–3) 0.11 0.51
Age at onset,  yearb 61 (48–69) 63 (52–70) 60 (42.5–68.5) 0.09 54 (40–64) 53 (40–63) 54.5 (41–64) 0.34 0.002
HAM-D  baselineb 19 (17–22) 18 (16–20) 21 (18–24)  < 0.0001 20 (17–23) 19 (17–22) 21 (18–23)  < 0.0001 0.16
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(47.06%). Because of the exclusion of variants detected in less than two samples from the association analysis, 
we observed a lower novel variants rate (calculated as the number of variants that matched with dbSNP/the 
number of variants in the final set) in our final variant set. We first carried out genome-wide association analysis 
using the final variant set, 13,318,214 variants, called from WGS in the discovery set. The association test results 
revealed no variant with a genome-wide significance threshold of 5 × 10–8 when considering both response to 
and remission following antidepressant treatment. However, 18 variants (17 SNVs and 1 INDEL) and another set 
of 18 variants (16 SNVs and 2 INDELs) showed a P value < 10–5 for remission following antidepressant treatment 
(Supplementary Table S1) and response to antidepressant treatment, respectively (Supplementary Table S2).
Identification of novel candidate variants associated with remission following antidepressant 
treatment in the discovery set. For WGS analysis, we focused on the penetrating LOF mutations known 
to disrupt protein function (Fig. 1) rather than common signals. We identified four SNVs predicted to be stop-
gained SNVs among the variants (Table 2). The four SNVs (rs1476860, rs3213755, rs139506139, and rs877346) 
resided close to the genes OR1B1, keratin-associated protein 1–1 (KRTAP1-1), SRRM5, and KRTAP13-2, respec-
tively. As a representative SNV, rs3213755 was found to be located in KRTAP1-1 as an LOF variant that could 
block gene translation and induce the disruption of protein function; it showed the most significant associa-
tion with remission following antidepressant treatment in the discovery set (p = 0.0184, OR 3.09, 95% confi-
dence interval [CI] 1.22–7.80). Additionally, rs1476860 (p = 0.077, OR 4.33, 95% CI 0.92–20.43), rs139506139 
(p = 0.044, OR 0.07, 95% CI 0.0037–1.48), and rs877346 (p = 0.055, OR 2.49, 95% CI 1.01–6.12) were selected as 
candidate variants associated with remission in the discovery set.
Validation of candidate variants associated with remission following antidepressant treat‑
ment in the replication set. A focused replication study was performed on these four candidate SNVs 
(rs1476860, rs3213755, rs139506139, and rs877346; Table 2). Of the four SNVs, rs3213755 showed a significant 
association with remission (p = 0.0027, OR 1.75, 95% CI 1.22–2.53]) in the replication set (n = 553). In a com-
bined analysis of both the discovery and replication sets, rs3213755 showed a significant association with remis-
sion (p = 0.00017, OR 1.90, 95% CI 1.36–2.67). The frequency of the rs3213755 A allele in the non-remission 
group from the discovery and replication sets was higher than that in the remission group (0.32 vs. 0.21 in the 
combined set). Notably, when only one SSRI (escitalopram) was considered, rs3213755 also showed a significant 
association (p = 0.00014, OR 2.75, 95% CI 1.63–4.65) in the combined set (Supplementary Table  S3). In the 
multivariate analysis, considering confounding factors, subjects possessing the LOF allele (A) of rs3213755 had 
a lower probability of achieving remission following antidepressant treatment, which was expected. The associa-
tion between rs3213755 and remission after SSRI treatment was robust after adjusting for variables including 
age, sex, family history of depression, number of episodes, age of onset, and baseline HAM-D score in the repli-
cation set (p = 0.0055, OR 1.71, 95% CI 1.17–2.49). However, rs1476860 (p = 0.517), rs139506139 (p = 0.296), and 
Discovery of candidate LOF variants
166 LOF variants predicted from whole genome sequencing
Korean patients with MDD (n=100; remitted n=36 vs. non-remitted n= 64)
Replication set
for 19 LOF candidate variants
Korean patients with MDD (n=553; remitted n=185 vs. non-remitted n= 368)
Combined analysis for verification
for four LOF candidate variants 
Korean patients with MDD (n=653; remitted n=221 vs. non-remitted n= 432)
Carrier-based Fisher’s exact test
- P < 0.1 for detection LOF variants
Carrier-based Fisher’s exact test
- P < 0.05
Figure 1.  Schematic workflow.
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rs877346 (p = 0.292) did not show a significant association with remission after SSRI treatment in the replication 
set.
Co‑expressed genes associated with KRTAP1‑1 from the in silico analysis and quantification in 
human brain tissue. To gain further information on the function and associated pathways of KRTAP1-1, 
we additionally identified 20 genes related to KRTAP1-1 from the GeneMANIA database, reflecting gene–gene 
interactions, co-expression patterns, and protein domains (Supplementary Fig. S2). Among these 20 genes, three 
genes (NTF3, GRIA4, and ARG2) were chosen based on functional evidence related to drug targets, neuro-
logical functions, and expression profiles in brain tissues. Finally, we quantified the expression of the four genes 
(KRTAP1-1, NTF3, GRIA4, and ARG2) in 22 temporal lobe tissue samples using qPCR. The results showed that 
all three genes (NTF3, GRIA4, and ARG2) along with KRTAP1-1 were expressed in the temporal lobe tissues of 
the human brain. The LOF variant, rs3213755, with the A allele was directly and significantly associated with the 
lower expression of the KRTAP1-1 gene in brain tissues (p = 0.045, Fig. 2). No significant association between the 
genotype and clinical characteristics of the subjects such as age or sex, was observed in this expression analysis 
(p > 0.05). Additionally, NTF3 expression was highly positively correlated with KRTAP1-1 expression in brain 
tissues based on Pearson’s correlation analysis (r = 0.84, p = 1.04 × 10–6, Supplementary Fig. S3).
Quasi‑replication and replication of previous genetic studies on the antidepressant 
response. Among the top 100 SNPs reported in previous GWASs on the antidepressant  response15 in Korean 
populations (Supplementary Table  S4), 11 variants showed significant associations with remission following 
SSRI treatment in our WGS results in the quasi-replication analysis (nominal threshold p < 0.05). Of these top 
100 SNPs, 75 (75.0%) showed an identical direction to the previous GWAS and our WGS results. In the repli-
cation analysis, 27 SNPs showed significant associations (nominal threshold p < 0.05) with a response to SSRI 
treatment in our WGS results. Additionally, we obtained 90 (90.0%) variants with a concordance of direction in 
both studies. No variant was replicated in a previous candidate genetic study that investigated neurotransmitter-
related genes (Supplementary Table S5)27. Among the SNPs reported in a previous meta-analyses of the antide-
pressant response in populations of European ancestry (p < 0.0001)28, only two SNPs (rs7597171 and rs2516808) 
were associated with remission, whereas three SNPs (rs7597171, rs943347, and rs2826852) were associated with 
a response in our WGS study (Supplementary Table S6).
Table 2.  Candidate loss-of-function variants associated with remission following SSRI treatment in patients 
with MDD (discovery set, n = 100; replication set, n = 553). MAF minor allele frequency, OR odds ratio, CI 
confidence interval, SNP single nucleotide polymorphism, NA not available. † Physical position based on 
human reference genome build hg 19 (GRCh37). ‡ p value and OR were calculated using a dominant disease 
model. The dominant allele is a test for the minor allele. *p value was calculated using a recessive disease 
model. a In the discovery set, remitted, n = 36; non-remitted, n = 64; in the replication set, remitted, n = 185; 
non-remitted, n = 368.







remitted p  value‡
OR (CI, 
95%)‡
9 rs1476860 125391241 OR1B1 A/G
Discovery 0.391 0.333 0.077* 4.33 (0.92–20.43)*
Replication 0.370 0.370 0.517* 1.21 (0.72–2.04)*
Combined 0.373 0.364 0.155* 1.44 (0.88–2.35)*
17 rs3213755 39197499 KRTAP1-1 A/G
Discovery 0.234 0.125 0.0184 3.09 (1.22–7.80)
Replication 0.331 0.228 0.00269 1.75 (1.22–2.53)
Combined 0.316 0.211 0.00017 1.90 (1.36–2.67)
19 rs139506139 44117804 SRRM5 T/C




Replication 0.012 0.022 0.296 0.55 (0.21–1.46)
Combined 0.010 0.025 0.054 0.41 (0.17–1.00)
21 rs877346 31744127 KRTAP13-2 T/A
Discovery 0.266 0.125 0.055 2.49 (1.01–6.12)
Replication 0.190 0.160 0.292 1.23 (0.84–1.80)
Combined 0.201 0.155 0.080 1.37 (0.97–1.95)
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Association between candidate variants and the antidepressant response in the discovery and 
replication sets. The association between rs3213755 and the antidepressant response to SSRI treatment was 
not significant in the discovery set (p = 0.30, OR 1.64, 95% CI 0.72–3.72); it showed a significant association in 
the replication set (p = 0.00041, OR 1.86, 95% CI 1.32–2.61). Additionally, three SNVs, rs115678527 (p = 0.081, 
OR 0.12, 95% CI 0.0067–2.32), rs7021123 (p = 0.078, OR 0.10, 95% CI 0.0057–1.89), and rs1476860 (p = 0.096, 
OR 2.61, 95% CI 0.85–8.04), were identified as candidates associated with the antidepressant response in the 
discovery set. However, these SNVs (rs115678527; p = 1.00, rs7021123; p = 0.81, and rs1476860; p = 0.71) did 
not show a significant association with the response after SSRI treatment in the replication set (Supplementary 
Table S7).
Discussion
We identified a novel LOF variant in KRTAP1-1, keratin-associated protein 1–1, that is associated with outcome 
of SSRI antidepressant therapy in patients with MDD. This variant, rs3213755, was identified using WGS. Its 
association with the treatment outcome of SSRI antidepressant therapy was validated in an independent set of 
patients with MDD (Table 1, Supplementary Table S8). The functional relevance between this variant and its 
expression was also evaluated in human brain tissues. Our results suggest that rs3213755 is an important vari-
ant associated with KRTAP1-1 knock-out and that it is related to remission following antidepressant treatment.
A null mutation in KRTAP1-1 could be caused by rs3213755; it can also be caused by additional LOF variants 
located in other coding regions. However, the only type of inactivating variant, rs3213755, known to produce 
a gene product with a minor or no function, was identified using WGS in the discovery set. We confirmed that 
the existence of the A allele of rs3213755 directly reduced the expression of KRTAP1-1 in an in vitro experiment 
using human brain tissues (Fig. 2). Thus, KRTAP1-1 may contribute as a mediator of the treatment outcome of 
remission following antidepressant therapy.
KRTAP1-1, a member of the keratin-associated protein (KAP) family located on chromosome 17q21.2, and 
encodes for a protein that forms a matrix of keratin intermediate filaments. KRTAP1-1′s function in the antide-
pressant effect has not been extensively investigated. Furthermore, its biological relevance in the human brain 
has not been systemically elucidated. However, although relatively low-expressed transcripts have not been 
detected in database such as Genotype-Tissue Expression (GTEx) based on RNA-sequencing, they can be meas-
ured using a more sensitive RT-qPCR  method29,30. Accordingly, we investigated whether the genes co-expressed 
with this gene were associated with depression or the action mechanism of antidepressants. The KRTAP1-1 
transcript expression was highly correlated with NTF3 expression in the temporal lobe of the human brain 
(Supplementary Fig. S2). Notably, the co-expressed gene, NTF3, can regulate cellular proliferation and apoptosis 
in  keratinocytes31. NTF3 is widely distributed in the cerebral hippocampus. It regulates neuronal development 
and promotes hippocampal  plasticity32. A previous study using a mouse depression model showed that NTF3 
infusion could modulate the neurotransmitters, such as serotonin and noradrenaline, which are the major tar-
gets of currently used  antidepressants33. NTF3 was found to be significantly elevated in the temporal region of 
Figure 2.  The loss-of-function variant, rs3213755, leads to low expression of the KRTAP1-1 gene in brain 
tissues. Expression levels are presented as minus ΔCt (GAPDH Ct value—TargetGene Ct value). Statistical 
analysis was performed using Wilcoxon’s rank-sum test. The association test was considered as a dominant 
model for the minor allele (A). Statistical analysis was performed using Wilcoxon’s rank-sum test. One sample 
with extremely high expression was excluded from the statistical analysis as an outlier.
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postmortem brain tissues of patients with depression who were taking  antidepressants34. Thus, genes within the 
KRTAP1-1 co-expression network, including NTF3, may be involved in the antidepressant action mechanism.
Previous GWASs using genotyping arrays have reported genetic markers associated with remission or a 
response following antidepressant  treatment10–14. However, most of the top SNPs from these studies, including 
our GWAS  study15, were not replicated in our WGS results (Supplementary Table S4). Additionally, SNPs that 
showed significant associations with remission after SSRI treatment in this study were not reported in those 
previous studies. The main reason for these discrepant results is that our discovery set has a limited sample 
size to validate previous results that had a sufficient statistical power. In addition, our identified genetic vari-
ants (rs3213755) from the KRTAP1-1 gene were not observed in previous GWASs. In terms of technology, this 
SNP was not included in either the array-based chip platform or the HapMap3 database used for imputation 
in a previous meta-analysis of pharmacogenetic studies on the antidepressant  response28. Therefore, this LOF 
variant was rarely included in previous studies based on array-chip  platforms10–14, although rs3213755 is not a 
rare variant in all  populations35. In addition, a relatively large proportion of elderly patients and differences in 
ethnicity and antidepressants could be possible factors that caused the lack of agreement between our results 
and previous GWASs.
Previous pharmacogenetic studies on antidepressant therapy focused on the response rather than remission. 
The remission always has a lower rate than response, thus studies for remission need more sample size or larger 
effect size. However, remission is more important outcome than response in depressive patients. A response 
without remission after antidepressant treatment is associated with a lower degree of functional improvement 
and higher risk of  relapse5,36. Our study provides fundamental information that can serve as the basis for a larger 
WGS study designed to find genetic markers for remission.
This study has several limitations. First, our sample size in the discovery set was insufficient to analyze all the 
variants identified in the WGS due to high  cost37. Although we assessed only 100 patients with MDD following 
SSRI treatment, our study enrolled ethnically homogeneous patients and categorized them appropriately. In 
addition, our results were validated in an independent replication set, in which the same protocol for patient 
enrollment was applied. With approximately 10 million independent variants generated using WGS, reaching a 
genome-wide threshold is very unlikely to identify variants associated with a rare allele frequency, low relative 
risk, and low fraction of variance explained, even if they are the causal  variants38. Therefore, using lenient p-value 
thresholds (p < 0.1 for discovery)39, we focused on LOF variants with a high-penetrance conferring moderate 
or high risk, even if those were common allelic frequency, showing evidence for pathway-related co-expression 
in human cerebral tissue. Second, there might have been a potential bias related to the physician’s independent 
choice of antidepressant drug because of the study’s naturalistic design of the study. Additionally, in line with 
previous GWASs on antidepressant  response10–13, our study did not include a placebo-treated group. Third, our 
patients were mostly elderly patients. Thus, the generalizability of our results to patients with depression in other 
age groups may be limited.
Thus, we observed a significant association between remission to SSRI treatment and a LOF variant, 
rs3213755, in the KRTAP1-1 gene in elderly Korean patients with depression. Our functional study using tem-
poral lobe samples is the first step in finding functional evidence between the variant and expression of KRTAP1-1 
in brain tissues. Although functional evidence has been suggested in the animal model systems or biochemical 
studies, its real function in human brain is not well understood. We believe that KRTAP1-1 expression in brain tis-
sue may aid in the elucidation of the biological mechanisms of antidepressant drug action and assist in developing 
precision medicine guidelines for the genomic-based selection of antidepressant treatments. Moreover, additional 
WGS-based pharmacogenetic studies enrolling various ethnic populations with larger sample sizes are required.
Methods
Definition of cohorts. Patients in the discovery set were recruited from the Geropsychiatry Clinic of 
Samsung Medical Center (n = 100, SMC, Seoul, Korea). We enrolled SSRI-treated patients with depression for 
WGS. All patients were treated with an SSRI (escitalopram). We included 553 additional independent completer 
patients in the SSRI replication set from the Affective Disorder Clinic of SMC (n = 486)40 and Korea University 
Medical Center (n = 67; KUMC, Seoul, Korea)15. All enrollment processes including inclusion and exclusion 
criteria, antidepressant treatment, and collecting variables were identical for the replication and discovery sets. 
Consistent with the current pharmacogenetic strategy related to antidepressants, this study was conducted in 
naturalistic clinical settings rather than as a placebo-controlled clinical  trial10,11,15.
Inclusion and exclusion criteria. The subjects had to meet the following inclusion criteria: (1) 
age ≥ 18 years, (2) experiencing a current unipolar major depressive episode verified by the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition – Text Revision (DSM-IV-TR) criteria for  MDD40,41, and (3) 
be capable of providing informed consent. Diagnosis was based on an initial clinical interview at the clinic, fol-
lowed by a structured research assessment using the Samsung Psychiatric Evaluation  Schedule15, which included 
a semi-structured clinical interview for DSM-IV (SCID)42. In accordance with routine clinical procedures, these 
interviews were individually conducted for each patient. Clinical observations, medical records, past psychiatric 
histories, and the results of the SCID were assessed by a board-certified psychiatrist before the final diagnosis 
was made. The minimum score on the 17-item Hamilton scale for depression (HAM-D)43 required for enroll-
ment at baseline was 15. The exclusion criteria were (1) pregnancy, significant medical conditions, abnormal 
laboratory baseline values, or unstable psychiatric features (e.g., suicide attempt in the current episode); (2) a 
history of substance dependence, seizure, or neurological illness; or (3) concomitant DSM-IV axis I psychiatric 
disorders (schizophrenia, bipolar affective disorder, primary diagnoses of adjustment disorder, or post-trau-
matic stress disorder). Patients with MDD who met the DSM-IV criteria for the specifier “severe with psychotic 
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features” were excluded because they were normally taking concurrent antipsychotic medication. None of the 
patient had received antipsychotics for the current episode before enrollment. Likewise, no patient had received 
an antidepressant within 2 weeks before enrollment. Additionally, we verified that no patient had received fluox-
etine (known to have a long half-life) within the preceding 4 weeks. Most participants overlapped with the par-
ticipants in our previous GWAS (discovery sample 99/100 and replication sample 415/553)15.
Procedures. Patients received monotherapy for 6 weeks with an antidepressant drug. In the discovery cohort, 
100 patients received one SSRI (escitalopram), whereas, in the replication cohort, 553 patients were adminis-
tered monotherapy with escitalopram, fluoxetine, paroxetine, or sertraline as a permissible SSRI (Table 1). Dose 
titration was completed within two weeks. Blood samples were withdrawn at the end of the 6th week to estimate 
plasma drug concentrations. Patients were allowed to take lorazepam (0.5–1 mg) at bedtime for insomnia.
Patients were examined by a psychiatrist who monitored adverse events using the Udvalg for Kliniske Under-
sogelser (UKU)  scale44. Symptom severity was evaluated using the HAM-D by a trained rater every 2 weeks. All 
raters had HAM-D training. The HAM-D and genotype data were not disclosed to the psychiatrist. The rater was 
blinded to the genotype data. To maintain blinding, a trained research coordinator managed the participants’ data 
and schedules of participants. At 6 weeks, remission was defined as a HAM-D score < 8. According to standard 
conventions, a positive response to treatment is defined as a ≥ 50% decrease in the HAM-D  score45,46.
The replication set also included 67 patients recruited from the Pharmacogenomic Research Center for 
Psychotropic Drugs of the Department of Psychiatry, KUMC. The procedures followed at this site were very 
similar to those described for the SMC patients. Detailed protocols are available in previous KUMC  reports47,48.
Ethical approval. The protocol was approved by the Ethics Review Board of the SMC and the Ethics Com-
mittee of the KUMC, and the procedures were performed according to national ethical guidelines.
Informed consent. Written informed consent was obtained from all participants.
WGS analysis and genotyping. WGS data were generated using an Illumina HiSeq X Ten platform. 
Library construction and sequencing (150-bp paired-end reads) were performed according to the manufacturer’s 
instructions. The average depth showed 30 × coverage of the whole genome. Sequencing fastq data were aligned 
with reference genome hg19 containing the decoy sequence using the BWA-mem algorithm of BWA 0.7.1049. 
Duplicate reads were removed using Picard 1.1 (https ://broad insti tute.githu b.io/picar d/). Realignment of small 
INDELs and recalibration of base quality scores were performed using previously known sites (from dbSNP138, 
Mills and 1000G gold standard INDELs b37 sites, and 1000G phase1 INDELs b37) after removing duplicate 
reads using GenomeAnalysisTK-3.3-0 (GATK)50. Variants were called using HaplotypeCaller in GATK. Var-
iant annotation was conducted using ANNOVAR for RefGene, dbSNP 147, and population frequency from 
 gnomAD51. In total, 13,318,214 variants (SNPs and INDELs) were obtained from the raw variant call set after 
excluding mitochondrial variants. We applied the following hard filter criteria: (1) separating multi-allelic vari-
ants, (2) including variants with a total read depth of over 6, (3) including variants with an alternative read depth 
of over 3, (4) excluding variants with an allelic frequency < 0.1 for SNPs and < 0.2 for INDELs, and (5) excluding 
variants detected in less than two samples. Loss-Of-Function Transcript Effect Estimator (LOFTEE; https ://githu 
b.com/konra djk/lofte e) was implemented as a variant effect predictor (VEP) to predict high-confidence or low-
confidence LOF  mutations52. In total, 166 LOF mutations were predicted with high confidence using LOFTEE 
(https ://githu b.com/konra djk/lofte e). Overall, we identified 19 variants (7 SNVs and 12 small INDELs) associ-
ated with remission. They were annotated as LOF variants with a nominal association P value < 0.1. Additionally, 
we identified 15 variants (3 SNVs and 12 small INDELs) associated with a positive response treatment outcome 
to antidepressant therapy after applying the same criteria as used for remission. Next, we manually confirmed 
the existence of variants by capturing relevant regions using an integrative genomics viewer  screenshot53. The 
library preparation and clustering methods for WGS were performed as described in the Supplementary Mate-
rial.
All replication samples were genotyped using TaqMan SNP Genotyping Assays. Detailed descriptions of the 
genotyping methods for the replication samples are provided in the Supplementary Material.
Selection of co‑expressed genes using an in silico analysis and quantification in brain tis‑
sue. To identify functional association networks in public databases, we used the GeneMANIA system (https 
://genem ania.org) to help predict the candidate gene  functions54. In total, 22 brain tissues acquired from a popu-
lation of ethnic Korean individuals who had undergone temporal lobectomy for hippocampal sclerosis were 
used for expression quantification (16 females and 6 males, mean age = 36.5 years [standard deviation = 13.9]). 
None of the temporal lobectomy specimens showed histological abnormalities. Target gene primers for perform-
ing qPCR were designed to quantify the expression of each gene. Detailed descriptions of the in silico analysis 
and in vitro experiments are provided in the Supplementary Material.
Statistical analyses. All statistical analyses, including the association analyses, were performed using 
PLINK, version 1.09 years55, and R statistical software (version 3.2.0). We used Fisher’s exact test to calculate 
the associations between genotypes and treatment outcomes. Continuous variables are presented as the median 
and interquartile range. Wilcoxon’s rank-sum test was used to compare the continuous variables among groups. 
Categorical variables are summarized as frequencies and proportions. The chi-square test was used to compare 
groups with respect to categorical variables. We employed multiple logistic regression to adjust for confounding 
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factors that showed significant differences between the remission and non-remission group or the discovery and 
replication set. Gene expression correlation analysis was performed using Pearson’s correlation test. Addition-
ally, we employed multiple logistic regression analysis for each significant SNV after adjusting for the possible 
confounding variables. We examined the reproducibility of previously reported 100 SNPs and 10 SNPs reported 
by Myung et al. (Supplementary Table S4) and Lim et al. (Supplementary Table S5), respectively, in the WGS 
discovery set. We applied nominal threshold of p < 0.05 for quasi-replication and replication of previous genetic 
studies on the antidepressant response. The direction of effect was estimated by the odds ratio calculated in each 
study. Statistical significance was defined as p < 0.05 or less, with the exception that statistical significance for 
LOF was defined as a less stringent cut off of p < 0.1, because our small sample size could hide true associations 
trending toward significance. To overcome the low statistical power resulting from the small sample size, more 
candidate variants were included in the replication set with a threshold p < 0.1.
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